Key Highlights
- Sun Pharmaceutical Industries is acquiring Organon & Co for $11.75 billion in an all-cash transaction, debt included.
- Shareholders of Organon will be paid $14.00 cash per share.
- Shares of Organon jumped approximately 31% Friday following initial reports, then surged another ~15% during Monday’s premarket session.
- The acquisition will create a pharmaceutical powerhouse with projected pro forma revenues reaching $12.4 billion, placing it among the world’s top 25 pharma companies.
- Completion of the transaction is anticipated in early 2027, subject to customary regulatory clearances and stockholder consent.
India’s leading pharmaceutical manufacturer, Sun Pharma, revealed on Sunday its intention to acquire Organon & Co, headquartered in New Jersey, through an entirely cash-financed transaction valued at $11.75 billion when debt is factored in. Shareholders will receive $14.00 for each share they own.
Shares of Organon had already experienced a significant rally of nearly 31% on Friday following an Economic Times report suggesting Sun Pharma was negotiating a roughly $13 billion acquisition. After Sunday’s formal announcement confirmed the transaction, Organon shares climbed an additional ~15% in premarket activity on Monday.
Combined across both trading sessions, the stock has risen approximately 46% from its pre-announcement trading levels.
Organon became an independent entity following its separation from Merck in 2021 and specializes in women’s healthcare products, biosimilar medications, and established branded pharmaceutical products. The company generated $6.2 billion in revenue and posted adjusted EBITDA of $1.9 billion throughout 2025.
Sun Pharma indicated it will finance the acquisition using existing cash reserves combined with committed bank credit facilities. Both companies’ boards of directors have given their approval to the transaction.
Strategic Value for Sun Pharma
The acquisition provides Sun Pharma with immediate access to a diverse portfolio exceeding 70 products distributed across more than 140 nations worldwide. The deal also establishes the Indian pharmaceutical giant’s entry into the biosimilars sector, where the combined organization would rank as the seventh-largest competitor globally.
Organon maintains strong market positions in the United States, Europe, China, Canada, and Brazil. The company runs six production facilities located throughout the European Union and emerging market regions.
Dr. Kunal, an analyst with Macquarie, characterized the transaction as “strategically and financially compelling” for Sun Pharma. He highlighted that the merged company will derive 27% of revenues from innovative pharmaceutical products, an increase from Sun Pharma’s current 20% share.
Sun Pharma has established expertise in dermatology, ophthalmology, and onco-dermatology within its innovative medicines division. Incorporating Organon’s comprehensive women’s health product line would significantly broaden that therapeutic reach.
The merged organization would also establish itself as one of the top three competitors in the global women’s health pharmaceutical market.
Financial Leverage Considerations
Organon enters this transaction with outstanding debt of $8.6 billion and available cash of $574 million as reported in December 2025. The company’s net debt to EBITDA multiple was 4 times prior to the deal announcement.
Sun Pharma, conversely, maintained a net cash positive financial position before announcing the acquisition. Following the transaction’s completion, analysts project the combined company will operate with a net debt to EBITDA ratio of 2.3 times.
Bhavesh Shah from Equirus Capital observed that acquisitions of this magnitude can prove “value accretive over the medium to long term,” while cautioning about potential near-term headwinds such as integration expenses and implementation complexities.
This represents Sun Pharma’s sixth major acquisition over the past 16 years. Historical transactions include the 2007 purchase of struggling Israeli pharmaceutical company Taro Pharma and the 2014 acquisition of Ranbaxy Laboratories for approximately $3.2 billion.
The Organon acquisition is projected to elevate Sun Pharma into the ranks of the top 25 pharmaceutical companies worldwide, achieving combined pro forma revenues of $12.4 billion.
The deal is slated to reach completion in early 2027, contingent upon receiving necessary regulatory approvals and shareholder authorization.
